Ocular Therapeutix Q3 net loss $36.5M; SOL-1 topline data expected Q4 2025

OCULAR THERAPEUTIX, INC

2024-Q3 EPS reported -$0.94 revenue$46,641,000

Net loss of $36.5M ($0.22 diluted EPS) vs $0.5M loss in Q3 2023; R&D spend jumped to $37.1M.
Total net revenue $15.4M (+2.3% YoY); DEXTENZA full-year 2024 revenue guided $62-67M.
Cash $427.2M as of Sep 30, 2024, expected to fund operations into 2028.
SOL-1 fully randomized by YE 2024 (accelerated); topline data now expected Q4 2025.
SOL-R trial open for direct enrollment after FDA Type C response; NDA support confirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.